NCT04960124View on ClinicalTrials.gov

A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 5, 2021

Primary Completion Date

November 19, 2021

Study Completion Date

November 19, 2021

Conditions
HealthyHepatic Impairment
Interventions
DRUG

JNJ-42847922

Participants will receive JNJ-42847922 tablet as a single oral dose (Dose 1 or Dose 2 or Dose 3) on Day 1.

Trial Locations (2)

24105

CRS Clinical Research Services Kiel GmbH, Kiel

81241

APEX GmbH, München

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04960124 - A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants | Biotech Hunter | Biotech Hunter